Yin M, et al. - Researchers estimated 88 cases to evaluate the prognostic values of mutations in ATM in tumors of subjects with relapsed/advanced (TxN_2-3M_0-1) urothelial cancer (UC) via 3 independent datasets. They observed the presence of ATM mutations in 14.8%, 11% and 6.2% of the 3 cohorts. They recorded a constant association of ATM mutations with a significantly shorter overall survival (OS) and with a poorer survival as well. Hence, they suggested ATM mutations, a negative prognostic biomarker in relapsed/advanced UC patients.